SPDR S&P Em S-Cap

Structure Therapeutics CEO says need to build relationships with primary care physicians

Structure Therapeutics predicts oral weight loss drugs will claim 25% to 50% of GLP-1 market

Janney Capital Management LLC Increases Stake in Structure Therapeutics Inc.

Structure Therapeutics Inc. Reveals Oral Obesity Treatment Pipeline

Gasherbrum Bio Grants Genentech GLP-1 Patent License

Structure Therapeutics Inc. Sponsored American Depositary Shares Recommended as 'Moderate Buy' by Brokers

HC Wainwright Raises Structure Therapeutics Target Price to $90

Structure Therapeutics' stock price rises 3% after Eli Lilly's oral obesity drug trial data release

Structure Therapeutics Inc. Launching ACCG-2671 Clinical Trial for Obesity Treatment

Structure Therapeutics Completes Upsized Public Offering Raising Approximately $747.5 Million

Structure Therapeutics Inc. Announces Increased Offering Pricing

H.C. Wainwright Maintains Buy Rating on Structure Therapeutics

Structure Therapeutics Inc. Announces Positive Phase 2b Clinical Trial Results for Oral GLP-1 Agonist

Structure Therapeutics to Release Aleniglipron Clinical Trial Data

Wall Street Analysts Maintain Buy Rating for Structure Therapeutics

Structure Therapeutics Reaffirmed With Buy Rating, Price Target Set at $100

Stifel Nicolaus analyst maintains buy rating on Structure Therapeutics

Structure Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.1414 (forecast USD -0.3677)

Structure Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.0115

Patrick Dolezal Maintains Buy Rating for Structure Therapeutics

Polaryx Therapeutics

Baird Medical Investment

Globavend

Leifras

Atomera

Innovation Beverage

Signing Day Sports

Gaxos.ai

Compass Pathways

MSCI

<p>Emerging market assets remained stable amid new tariff threats from U.S. President Trump, which dampened risk sentiment. The MSCI emerging markets stock index and currency index showed little change. Despite geopolitical tensions, emerging markets demonstrated resilience, with significant inflows into equity funds. Central and eastern European indexes mostly declined, while Egypt's index rose after futures trading approval. The IMF raised its 2026 global growth forecast to 3.3%, driven by AI investment expectations.</p>

Reuters

EMERGING MARKETS-EM assets muted as markets navigate fresh Trump tariff threats

SPDR S&P Em S-Cap(EWX.US)

EMERGING MARKETS-EM assets muted as markets navigate fresh Trump tariff threats